Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
Toxicol Pathol ; 47(4): 461-468, 2019 06.
Article in English | MEDLINE | ID: mdl-31018785

ABSTRACT

Anatomic pathology and clinical pathology end points are standard components of almost every nonclinical general toxicity study conducted during the risk assessment of novel pharmaceuticals and chemicals. On occasion, an ultrastructural pathology evaluation using transmission electron microscopy (TEM) may be included in nonclinical toxicity studies. Transmission electron microscopy is most commonly used when a light microscopic finding may require further characterization that could inform on the pathogenesis and/or mechanism of action. Regulatory guidance do not address the use of TEM in general study designs nor whether these assessments should be performed in laboratories conducted in compliance with Good Laboratory Practices. The Scientific and Regulatory Policy Committee of the Society of Toxicologic Pathology (STP) formed a Working Group to assess the current practices on the use of TEM in nonclinical toxicity studies. The Working Group constructed a survey sent to members of societies of toxicologic pathology in the United States, Europe, Britain, and Japan, and responses were collected through the STP for evaluation by the Working Group. The survey results and regulatory context are discussed, as are "points to consider" from the collective experience of the Working Group. This survey indicates that TEM remains an essential diagnostic option for complementing toxicologic pathology evaluations. *This Points to Consider article is a product of a Society of Toxicologic Pathology (STP) Working Group commissioned by the Scientific and Regulatory Policy Committee (SRPC) of the STP. It has been reviewed and approved by the SRPC and Executive Committee of the STP but it does not represent a formal Best Practice recommendation of the Society; rather, it is intended to provide key "points to consider" in designing nonclinical studies or interpreting data from toxicity and safety studies intended to support regulatory submissions. The points expressed in this document are those of the authors and do not reflect views or policies of the employing institutions. Readers of Toxicologic Pathology are encouraged to send their thoughts on these articles or ideas for new topics to the Editor.


Subject(s)
Microscopy, Electron, Transmission , Pathology, Clinical/methods , Toxicology/methods , Advisory Committees , Animals , Drug Evaluation, Preclinical/methods , Drug Evaluation, Preclinical/standards , Guidelines as Topic , Humans , Microscopy, Electron, Transmission/methods , Microscopy, Electron, Transmission/standards , Pathology, Clinical/legislation & jurisprudence , Pathology, Clinical/standards , Societies, Scientific , Toxicity Tests/methods , Toxicity Tests/standards , Toxicology/legislation & jurisprudence , Toxicology/standards , United States , United States Food and Drug Administration
2.
PLoS One ; 9(4): e94114, 2014.
Article in English | MEDLINE | ID: mdl-24714781

ABSTRACT

Memo is a conserved protein that was identified as an essential mediator of tumor cell motility induced by receptor tyrosine kinase activation. Here we show that Memo null mouse embryonic fibroblasts (MEFs) are impaired in PDGF-induced migration and this is due to a defect in sphingosine-1-phosphate (S1P) signaling. S1P is a bioactive phospholipid produced in response to multiple stimuli, which regulates many cellular processes. S1P is secreted to the extracellular milieu where it exerts its function by binding a family of G-protein coupled receptors (S1PRs), causing their activation in an autocrine or paracrine manner. The process, termed cell-autonomous S1PR signaling, plays a role in survival and migration. Indeed, PDGF uses cell-autonomous S1PR signaling to promote cell migration; we show here that this S1P pathway requires Memo. Using vascular endothelial cells (HUVECs) with Memo knock-down we show that their survival in conditions of serum-starvation is impaired. Furthermore, Memo loss in HUVECs causes a reduction of junctional VE-cadherin and an increase in sprout formation. Each of these phenotypes is rescued by S1P or S1P agonist addition, showing that Memo also plays an important role in cell-autonomous S1PR signaling in endothelial cells. We also produced conventional and endothelial cell-specific conditional Memo knock-out mouse strains and show that Memo is essential for embryonic development. Starting at E13.5 embryos of both strains display bleeding and other vascular problems, some of the phenotypes that have been described in mouse strains lacking S1PRs. The essential role of Memo in embryonic vascular development may be due in part to alterations in S1P signaling. Taken together our results show that Memo has a novel role in the S1P pathway and that Memo is needed to promote cell-autonomous S1PR activation.


Subject(s)
Cell Movement/physiology , Lysophospholipids/metabolism , Neovascularization, Physiologic/physiology , Nonheme Iron Proteins/metabolism , Signal Transduction/physiology , Sphingosine/analogs & derivatives , Animals , Apoptosis/physiology , Cell Proliferation/physiology , Lysophospholipids/genetics , Mice , Mice, Knockout , Nonheme Iron Proteins/genetics , Phosphotransferases (Alcohol Group Acceptor)/metabolism , Sphingosine/genetics , Sphingosine/metabolism
3.
Toxicol Pathol ; 42(7): 1105-16, 2014 Oct.
Article in English | MEDLINE | ID: mdl-24717899

ABSTRACT

Differences were examined between male and female Sprague-Dawley rats in the response of 16 urinary biomarkers (measured using several assay platforms) to renal injury produced by gentamicin administered subcutaneously for 10 days at a dosage of 75 mg/kg. Urinary biomarkers expressed as fold difference from contemporaneous controls and renal histopathology were assessed after 3 and 10 doses. On day 4, minimal proximal tubular changes were observed microscopically in all males but no females; on day 11, more extensive and more severe injury was observed to a similar extent in all animals of both sexes. Modest increases (maximum 5-fold) in all urinary biomarkers (except epidermal growth factor [EGF], which was decreased) on day 4 and marked elevations (maximum 271-fold) on day 11 were seen consistently in both sexes. However, the magnitude of the increases differed between the sexes. On day 4, despite the lack of tubular injury, many biomarkers were more elevated in females than males but this rarely led to statistically significant sex differences; only 2 biomarkers (ß2-microglobulin and total protein) showed a greater increase in males than females in line with the histopathology. On day 11, there were many more biomarkers that showed a statistically significant difference between the sexes in fold change with treatment; in line with the results on day 4, the majority of biomarkers were more increased in females than males. It remains unresolved if sex differences in the magnitude of biomarker response at injury threshold would lead to any difference in diagnostic interpretation between the sexes. These data highlight the need for publication of more studies using animals of both sexes to fully explore the influence of sex on the diagnostic performance of the novel biomarkers.


Subject(s)
Biomarkers/urine , Gentamicins/adverse effects , Kidney Diseases/pathology , Kidney/drug effects , Sex Factors , Animals , Dose-Response Relationship, Drug , Female , Gentamicins/administration & dosage , Kidney/pathology , Kidney Diseases/chemically induced , Male , Rats , Rats, Sprague-Dawley , beta 2-Microglobulin/urine
4.
FASEB J ; 28(1): 327-36, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24056085

ABSTRACT

Memo is a widely expressed 33-kDa protein required for heregulin (HRG)-, epidermal growth factor (EGF)-, and fibroblast growth factor (FGF)-induced cell motility. Studies in mouse embryonic fibroblasts, wild-type or knockout for Memo, were performed to further investigate the role of Memo downstream of FGFR. We demonstrated that Memo associates with the FGFR signalosome and is necessary for optimal activation of signaling. To uncover Memo's physiological role, Memo conditional-knockout mice were generated. These animals showed a reduced life span, increased insulin sensitivity, small stature, graying hair, alopecia, kyphosis, loss of subcutaneous fat, and loss of spermatozoa in the epididymis. Memo-knockout mice also have elevated serum levels of active vitamin D, 1,25-dihydroxyvitamin D3 (1,25(OH)2D), and calcium compared to control littermates expressing Memo. In summary, the results from in vivo and in vitro models support the hypothesis that Memo is a novel regulator of FGFR signaling with a role in controlling 1,25(OH)2D production and normal calcium homeostasis.


Subject(s)
Nonheme Iron Proteins/metabolism , Receptors, Fibroblast Growth Factor/metabolism , Animals , Calcitriol/blood , Calcium/blood , Cells, Cultured , Immunohistochemistry , Immunoprecipitation , Mice , Nonheme Iron Proteins/genetics , Vitamin D/blood
5.
Int J Hepatol ; 2012: 785786, 2012.
Article in English | MEDLINE | ID: mdl-23119170

ABSTRACT

The culture liver slices are mainly used to investigate drug metabolism and xenobiotic-mediated liver injuries while apoptosis and proliferation remain unexplored in this culture model. Here, we show a transient increase in LDH release and caspase activities indicating an ischemic injury during the slicing procedure. Then, caspase activities decrease and remain low in cultured slices demonstrating a low level of apoptosis. The slicing procedure is also associated with the G0/G1 transition of hepatocytes demonstrated by the activation of stress and proliferation signalling pathways including the ERK1/2 and JNK1/2/3 MAPKinases and the transient upregulation of c-fos. The cells further progress up to mid-G1 phase as indicated by the sequential induction of c-myc and p53 mRNA levels after the slicing procedure and at 24 h of culture, respectively. The stimulation by epidermal growth factor induces the ERK1/2 phosphorylation but fails to activate expression of late G1 and S phase markers such as cyclin D1 and Cdk1 indicating that hepatocytes are arrested in mid-G1 phase of the cell cycle. However, we found that combined stimulation by the proinflammatory cytokine tumor necrosis factor α and the epidermal growth factor promotes the commitment to DNA replication as observed in vivo during the liver regeneration.

6.
Toxicol Pathol ; 40(6 Suppl): 40S-121S, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22949412

ABSTRACT

The INHAND Project (International Harmonization of Nomenclature and Diagnostic Criteria for Lesions in Rats and Mice) is a joint initiative of the Societies of Toxicologic Pathology from Europe (ESTP), Great Britain (BSTP), Japan (JSTP), and North America (STP) to develop an internationally accepted nomenclature for proliferative and nonproliferative lesions in laboratory animals. The purpose of this publication is to provide a standardized nomenclature and differential diagnosis for classifying microscopic lesions observed in the male reproductive system of laboratory rats and mice, with color microphotographs illustrating examples of some lesions. The standardized nomenclature presented in this document is also available for society members electronically on the Internet (http://goreni.org). Sources of material included histopathology databases from government, academia, and industrial laboratories throughout the world. Content includes spontaneous and aging lesions as well as lesions induced by exposure to test materials. A widely accepted and utilized international harmonization of nomenclature for lesions of the male reproductive system in laboratory animals will decrease confusion among regulatory and scientific research organizations in different countries and provide a common language to increase and enrich international exchanges of information among toxicologists and pathologists.


Subject(s)
Biomedical Research/standards , Genital Diseases, Male/pathology , Genitalia, Male/pathology , Terminology as Topic , Animals , Animals, Laboratory , Genital Diseases, Male/classification , Genitalia, Male/chemistry , Genitalia, Male/cytology , Histocytochemistry , Male , Mice , Rats
7.
Toxicol Pathol ; 39(7): 1115-28, 2011 Dec.
Article in English | MEDLINE | ID: mdl-22006284

ABSTRACT

Kidney is a major target organ in preclinical studies. In recent years, intense research has been undertaken to characterize novel renal toxicity biomarkers. In this context, we studied nephron segment specific antibodies against aquaporin-1 (AQP-1), α-glutathione-S-transferase (alpha-GST), Tamm-Horsfall protein (TH), calbindin-D(28K) (CalD), and aquaporin-2 (AQP-2), using an immunoperoxidase method on formalin-fixed paraffin-embedded kidney tissues of dogs, rats, mice, and Cynomolgus monkeys. AQP-1 was specific for proximal tubules and thin descending limbs of Henle's loops and AQP-2 for connecting and collecting ducts in dogs, rats, mice, and Cynomolgus monkeys. Alpha-GST stained the straight part of proximal tubules in dogs and proximal convoluted tubule and straight part of proximal tubules in rats. TH was specific for thick ascending limbs of Henle's loops in mice, rats, dogs, and Cynomolgus monkeys and stained additionally scattered cells in cortical connecting/collecting ducts of dogs. CalD was found in distal convoluted tubules and cortical connecting and collecting ducts of dogs, rats, and mice and in distal convoluted tubules, connecting ducts, and cortical and medullary collecting ducts of Cynomolgus monkey. This panel of antibodies may be a helpful tool to identify renal tubules by light microscopy in preclinical studies and to validate new biomarkers of renal toxicity.


Subject(s)
Aquaporins/analysis , Glutathione Transferase/analysis , Nephrons/chemistry , S100 Calcium Binding Protein G/analysis , Uromodulin/analysis , Animals , Biomarkers/chemistry , Calbindins , Dogs , Immunohistochemistry , Macaca fascicularis , Mice , Rats , Species Specificity
8.
J Cell Sci ; 122(Pt 6): 787-97, 2009 Mar 15.
Article in English | MEDLINE | ID: mdl-19223396

ABSTRACT

Heregulin (HRG) activates ErbB2-ErbB3 heterodimers thereby stimulating many cellular responses, including motility. Memo and PLCgamma1 interact with ErbB2 autophosphorylation sites and are essential for HRG-induced chemotaxis. By tracing HRG-stimulated cell migration in Dunn chambers, we found that Memo- or PLCgamma1 knockdown (KD) strongly impairs cell directionality. Memo has no obvious enzymatic activity and was discovered via its ability to complex with ErbB2. Using the yeast two-hybrid approach to gain insight into Memo function, an interaction between Memo and cofilin, a regulator of actin dynamics, was uncovered. The interaction was confirmed in vitro using recombinant proteins and in vivo in co-immunoprecipitation experiments where Memo was detected in complexes with cofilin, ErbB2 and PLCgamma1. Interestingly, in Memo KD cells, HRG-induced PLCgamma1 phosphorylation was decreased, suggesting that Memo regulates PLCgamma1 activation. Furthermore, HRG-induced recruitment of GFP-cofilin to lamellipodia is impaired in Memo and in PLCgamma1 KD cells, suggesting that both proteins lie upstream of cofilin in models of ErbB2-driven tumor-cell migration. Finally, in vitro F-actin binding and depolymerization assays showed that Memo enhances cofilin depolymerizing and severing activity. In summary, these data indicate that Memo also regulates actin dynamics by interacting with cofilin and enhancing its function.


Subject(s)
Actin Depolymerizing Factors/metabolism , Cell Movement , Neoplasms/enzymology , Neoplasms/pathology , Nonheme Iron Proteins/metabolism , Phospholipase C gamma/metabolism , Receptor, ErbB-2/metabolism , Actins/metabolism , Biological Assay , Breast Neoplasms/enzymology , Breast Neoplasms/pathology , Cell Line, Tumor , Cell Movement/drug effects , Chemotaxis/drug effects , Enzyme Activation/drug effects , Green Fluorescent Proteins/metabolism , Humans , Intracellular Signaling Peptides and Proteins , Neuregulin-1/pharmacology , Phosphorylation/drug effects , Protein Binding/drug effects , Protein Transport/drug effects , Pseudopodia/drug effects , Pseudopodia/enzymology , Recombinant Fusion Proteins/metabolism
10.
J Pharmacol Exp Ther ; 309(1): 235-40, 2004 Apr.
Article in English | MEDLINE | ID: mdl-14718579

ABSTRACT

SanOrg123781A is a synthetic hexadecasaccharide that displays antithrombin-dependent inhibition of factor Xa and thrombin and potent antithrombotic effects. The antithrombotic activity of SanOrg123781A has been studied in a new mouse model of arterial thrombosis, where thrombus formation was induced by the application of an electrical current to the adventitial surface of a carotid artery. In this model, antiplatelet agents such as the ADP-receptor antagonist clopidogrel (30 mg/kg, p.o. 2 h before stimulation) and the GpIIb/IIIa antagonist SR121566A [3-(N-[4-(4-[amino(imino)methyl]phenyl)-1,3-thiazol-2-yl]-N-[1-(carboxymethyl)piperidin-4-yl]amino)propionic acid, trihydrochloride] (0.3 mg/kg, i.v. 5 min before stimulation) strongly prolonged the time to occlusion (TTO) (761 and 473% increases, respectively), whereas aspirin was devoid of antithrombotic activity. Standard heparin (2 mg/kg, i.v.), the low molecular weight heparin enoxaparin (20 mg/kg, i.v.), and the synthetic, antithrombin-dependent inhibitor of factor Xa fondaparinux (10 mg/kg, i.v.) were also active in this model (742, 707, and 602% TTO increases, respectively). Interestingly, SanOrg123781A was active at much lower doses than the other oligosaccharides (554% increase in TTO at 0.3 mg/kg, i.v. 5 min before stimulation). Low doses of SanOrg123781A administered in combination with low doses of clopidogrel led to a marked increase in TTO, which was statistically more important than the additive effects of the two compounds given alone. These results indicate that SanOrg123781A exerts a potent antithrombotic activity in a mouse model of arterial thrombosis when compared with reference compounds and show that the combination of SanOrg123781A with clopidogrel leads to a marked synergistic antithrombotic effect.


Subject(s)
Carotid Artery Injuries/drug therapy , Carotid Artery Thrombosis/drug therapy , Platelet Aggregation Inhibitors/therapeutic use , Polysaccharides/therapeutic use , Ticlopidine/analogs & derivatives , Ticlopidine/therapeutic use , Animals , Clopidogrel , Drug Synergism , Electric Injuries , Male , Mice , Mice, Inbred BALB C , Platelet Aggregation/drug effects , Platelet Aggregation Inhibitors/pharmacology , Polysaccharides/pharmacology , Thrombosis/metabolism , Ticlopidine/pharmacology
11.
Cancer Res ; 63(18): 5844-9, 2003 Sep 15.
Article in English | MEDLINE | ID: mdl-14522908

ABSTRACT

In human carcinomas, stromelysin-3/matrix metalloproteinase 11 (ST3, MMP11) expression by nonmalignant fibroblastic cells located in the immediate vicinity of cancer cells is a bad prognostic factor. Using mouse models of primary tumors, it has been demonstrated that ST3 is a key player during local invasion, favoring cancer cell survival in connective tissue through an antiapoptotic function. To investigate the ST3 impact on additional phases of cancer cell invasion, we developed mammary gland cancer prone MMTV-ras transgenic mice in wild-type (ras+/+;ST3+/+) or ST3-deficient (ras+/+;ST3-/-) genotype and studied their whole natural cancer history. The tumor-free survival and delay between the first ras oncogenic hit and primary tumor appearance increased in ras+/+;ST3-/- mice (P < 0.000001 and <0.0000007, respectively). A systematic search for occult primary tumors and metastases revealed, in addition to a lower total number and size of primary tumors (P < 0.02), an unexpected higher number of metastases (P < 0.01) in ras+/+;ST3-/- mice. Moreover, for a similar number and size of primary invasive tumors, ras+/+;ST3-/- mice developed more metastases, indicating that the cancer cells evolving in ST3-deficient stroma have an increased potential to hematogenous dissemination. We conclude that the ST3 microenvironment is a consistently active partner of invading cancer cells but that its function differs throughout cancer progression, being tumor enhancer or repressor in processes leading to local or distal invasion. Such a dual effect for an MMP might shed light, at least partially, for the absence of survival benefit for patients included in anti-MMP clinical trials.


Subject(s)
Cell Transformation, Viral/physiology , Genes, ras/physiology , Mammary Neoplasms, Experimental/enzymology , Mammary Neoplasms, Experimental/pathology , Mammary Tumor Virus, Mouse/physiology , Metalloendopeptidases/physiology , Animals , Female , Liver Neoplasms, Experimental/enzymology , Liver Neoplasms, Experimental/secondary , Lung Neoplasms/enzymology , Lung Neoplasms/secondary , Male , Mammary Neoplasms, Experimental/virology , Matrix Metalloproteinase 11 , Metalloendopeptidases/deficiency , Mice , Mice, Transgenic
12.
Proc Natl Acad Sci U S A ; 99(8): 5585-90, 2002 Apr 16.
Article in English | MEDLINE | ID: mdl-11943846

ABSTRACT

TRAF4 belongs to the tumor necrosis factor receptor-associated factor (TRAF) family of proteins but, unlike other family members, has not yet been clearly associated to any specific receptor or signaling pathway. To investigate the biological function of TRAF4, we have generated traf4-deficient mice by gene disruption. The traf4 gene mutation is embryonic lethal but with great individual variation, as approximately one third of the homozygous mutant embryos died in utero around embryonic day 14, whereas the others reach adulthood. Surviving mutant mice manifest numerous developmental abnormalities; notably, 100% of homozygous mutant mice suffer respiratory disorder and wheezing caused by tracheal ring disruption. Additional malformations concern mainly the axial skeleton, as the ribs, sternum, tail, and vertebral arches are affected, with various degrees of penetrance. Traf4-deficient mice also exhibit a high incidence of spina bifida, a defect likened to neural tube defects (NTD) that are common congenital malformations in humans. Altogether, our results demonstrate that TRAF4 is required during embryogenesis in key biological processes including the formation of the trachea, the development of the axial skeleton, and the closure of the neural tube. Considering the normal expression pattern of TRAF4 in neural tissues, we can conclude that TRAF4 participates in neurulation in vivo.


Subject(s)
Bone and Bones/abnormalities , Neural Crest/abnormalities , Neural Crest/embryology , Proteins/genetics , Proteins/physiology , Trachea/abnormalities , Animals , Blotting, Western , DNA, Complementary/metabolism , Exons , Homozygote , In Situ Hybridization , Mice , Mice, Inbred C57BL , Mice, Transgenic , Models, Genetic , Mutagenesis, Site-Directed , Neurons/cytology , Neurons/metabolism , Polymerase Chain Reaction , Spinal Dysraphism/genetics , TNF Receptor-Associated Factor 4 , Tumor Necrosis Factor Receptor-Associated Peptides and Proteins
SELECTION OF CITATIONS
SEARCH DETAIL
...